FreshLeaf Analytics is excited to release Australia’s most comprehensive medicinal cannabis .
Q1 was defined by greater price competition and availability of legal medicinal cannabis products in Australia, which is encouraging news for patients and underscores expectations of an explosion in patient numbers.
This report will be the fourth major publication from FreshLeaf, which has been covering the Australian medical cannabis industry since 2017, and is the leading source of information and data on the sector.
KEY HIGHLIGHTS:
600% increase in active patients in 2019
Patients taking medical cannabis forecast to triple in 2020
Number of products in market increased to 100 from 76 in 6 months
Product prices fell 17.4% on average from Q3 2019
Increase in lower cost product options
Daily patient dose increased more than 60% from Q3 2019
Cannabidiol (CBD) could become over-the-counter this year
Rhys Cohen, Principal Consultant of FreshLeaf
